[
  {
    "ts": null,
    "headline": "Eli Lilly telehealth deals to prevent sale of compounded GLP-1s",
    "summary": "Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites. Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals. Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=ec9513f640ef032864379a14fc4a55ac70e3547d17452cb6025dd439353fab53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749587239,
      "headline": "Eli Lilly telehealth deals to prevent sale of compounded GLP-1s",
      "id": 135171122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites. Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals. Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=ec9513f640ef032864379a14fc4a55ac70e3547d17452cb6025dd439353fab53"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index rising 1.2% and",
    "url": "https://finnhub.io/api/news?id=b7a8a23e76b3e6643cbf3218c2bcdb6adaf02af2a32678fe423c8492ccb6a3b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749585761,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 135171123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index rising 1.2% and",
      "url": "https://finnhub.io/api/news?id=b7a8a23e76b3e6643cbf3218c2bcdb6adaf02af2a32678fe423c8492ccb6a3b0"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers stock falls after Lilly rules out partnership",
    "summary": "Investing.com -- Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, effectively ruling out a potential deal with Hims.",
    "url": "https://finnhub.io/api/news?id=9fbd6ec5b368578a2dfdeb1e22ff639ea1e7f708b61db31c3f72d80e2e4b7f64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749584123,
      "headline": "Hims & Hers stock falls after Lilly rules out partnership",
      "id": 135171124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, effectively ruling out a potential deal with Hims.",
      "url": "https://finnhub.io/api/news?id=9fbd6ec5b368578a2dfdeb1e22ff639ea1e7f708b61db31c3f72d80e2e4b7f64"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: Lilly to Only Work With Telehealth Companies That Don't Sell Copycat Zepbound",
    "summary": "(Updates with Eli Lilly's response to a request for comment in the third paragraph.) Eli Lilly (L",
    "url": "https://finnhub.io/api/news?id=2bc712c9f9a00cafeb28870fa7d949ada3c0106092690bd26dc972f90a514339",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749578935,
      "headline": "Update: Market Chatter: Lilly to Only Work With Telehealth Companies That Don't Sell Copycat Zepbound",
      "id": 135171125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with Eli Lilly's response to a request for comment in the third paragraph.) Eli Lilly (L",
      "url": "https://finnhub.io/api/news?id=2bc712c9f9a00cafeb28870fa7d949ada3c0106092690bd26dc972f90a514339"
    }
  },
  {
    "ts": null,
    "headline": "Drug pricing reform talks with US government lack clarity, industry executives say",
    "summary": "(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.  President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay.  According to the order, the administration was to set \"most favored nation\" price targets within 30 days.",
    "url": "https://finnhub.io/api/news?id=4333645898d656fc9c6507d59c37af38c8adde357a5cd3728bb41ed13151f54d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749578610,
      "headline": "Drug pricing reform talks with US government lack clarity, industry executives say",
      "id": 135171126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.  President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay.  According to the order, the administration was to set \"most favored nation\" price targets within 30 days.",
      "url": "https://finnhub.io/api/news?id=4333645898d656fc9c6507d59c37af38c8adde357a5cd3728bb41ed13151f54d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Tuesday Afternoon",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index rising 1.6% and the Healt",
    "url": "https://finnhub.io/api/news?id=ab86be910198f3d846330963c46895dcbd6bf3ffddeebd77bdac1a50892f88b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749578351,
      "headline": "Sector Update: Health Care Stocks Higher Tuesday Afternoon",
      "id": 135169619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index rising 1.6% and the Healt",
      "url": "https://finnhub.io/api/news?id=ab86be910198f3d846330963c46895dcbd6bf3ffddeebd77bdac1a50892f88b3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=37a508e9b992e020b0a9c373013a22180fddac527f5f37683db0e267c603f768",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749573000,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 135180472,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=37a508e9b992e020b0a9c373013a22180fddac527f5f37683db0e267c603f768"
    }
  },
  {
    "ts": null,
    "headline": "American Century Growth Fund Q1 2025 Commentary",
    "summary": "We seek to invest in larger U.S. companies demonstrating they have improving businesses as opposed to absolute levels of growth. Read more here.",
    "url": "https://finnhub.io/api/news?id=f04a5c1d06c86e91a70dc22c8f006a9dff9ca94c83522255ec67416de86324d4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749571800,
      "headline": "American Century Growth Fund Q1 2025 Commentary",
      "id": 135170117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182159386/image_2182159386.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "We seek to invest in larger U.S. companies demonstrating they have improving businesses as opposed to absolute levels of growth. Read more here.",
      "url": "https://finnhub.io/api/news?id=f04a5c1d06c86e91a70dc22c8f006a9dff9ca94c83522255ec67416de86324d4"
    }
  },
  {
    "ts": null,
    "headline": "Energy and healthcare stocks power S&P 500 higher",
    "summary": "Energy and healthcare stocks power S&P 500 higher",
    "url": "https://finnhub.io/api/news?id=cc0019a50c1b5e092926d3332c100776f34e11d82fbce2a9fe0356ce1bac7aba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749563775,
      "headline": "Energy and healthcare stocks power S&P 500 higher",
      "id": 135180473,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Energy and healthcare stocks power S&P 500 higher",
      "url": "https://finnhub.io/api/news?id=cc0019a50c1b5e092926d3332c100776f34e11d82fbce2a9fe0356ce1bac7aba"
    }
  },
  {
    "ts": null,
    "headline": "Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?",
    "summary": "ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.",
    "url": "https://finnhub.io/api/news?id=5af4e1473048fde6653e3f9a23bb5c5d2f8061432f20b363e55638be9ed8970b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749560520,
      "headline": "Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?",
      "id": 135154589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.",
      "url": "https://finnhub.io/api/news?id=5af4e1473048fde6653e3f9a23bb5c5d2f8061432f20b363e55638be9ed8970b"
    }
  },
  {
    "ts": null,
    "headline": "Weight-Loss Drugs Pose Long-Term Threat To McDonald's: Analyst",
    "summary": "McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=1544851e7b6cc0be720c1084ad9e59ced6c87999e49d689584a88d14ca9351b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749558457,
      "headline": "Weight-Loss Drugs Pose Long-Term Threat To McDonald's: Analyst",
      "id": 135152983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=1544851e7b6cc0be720c1084ad9e59ced6c87999e49d689584a88d14ca9351b0"
    }
  },
  {
    "ts": null,
    "headline": "McDonald's Stock Bitten By Big Downgrade Over Weight-Loss Drugs",
    "summary": "McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=bf72a1614c6cfdcd75f6c260c3adf85483bd08f8475d62a1deb54d226c91c177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749558457,
      "headline": "McDonald's Stock Bitten By Big Downgrade Over Weight-Loss Drugs",
      "id": 135148183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=bf72a1614c6cfdcd75f6c260c3adf85483bd08f8475d62a1deb54d226c91c177"
    }
  },
  {
    "ts": null,
    "headline": "Scorpion, fresh off Lilly deal, spins out startup Antares",
    "summary": "Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets.",
    "url": "https://finnhub.io/api/news?id=8af2512475df76d4d6955a2962910661f82dde6fa6de87df6089f851b49eb168",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749557940,
      "headline": "Scorpion, fresh off Lilly deal, spins out startup Antares",
      "id": 135171128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets.",
      "url": "https://finnhub.io/api/news?id=8af2512475df76d4d6955a2962910661f82dde6fa6de87df6089f851b49eb168"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
    "summary": "Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
    "url": "https://finnhub.io/api/news?id=c79e8709911fb4702e0c8c4e9fa4d995089ea2d93190918c73ce94971e4e213d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749550474,
      "headline": "Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
      "id": 135150322,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c79e8709911fb4702e0c8c4e9fa4d995089ea2d93190918c73ce94971e4e213d"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Eli Lilly and Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08",
    "summary": "Presenter SpeechUnknown Analyst All right. Great. We're just about at time. So we can get started here. Welcome to the day 2 of Eli Healthcare Conference. The weather is still holding up. Thank God...",
    "url": "https://finnhub.io/api/news?id=f700d99fad7a49ad1fd4d9840ef139cb33770608e647e1934238560a2a7c8902",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749547219,
      "headline": "Transcript : Eli Lilly and Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08",
      "id": 135148313,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Presenter SpeechUnknown Analyst All right. Great. We're just about at time. So we can get started here. Welcome to the day 2 of Eli Healthcare Conference. The weather is still holding up. Thank God...",
      "url": "https://finnhub.io/api/news?id=f700d99fad7a49ad1fd4d9840ef139cb33770608e647e1934238560a2a7c8902"
    }
  },
  {
    "ts": null,
    "headline": "The Highest-Quality Dividend Contenders By Quality Scores",
    "summary": "The Highest-Quality Dividend Contenders By Quality Scores",
    "url": "https://finnhub.io/api/news?id=1a715141ace3b115707a223df8914be7859358185883c42415537be64b013a81",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749546000,
      "headline": "The Highest-Quality Dividend Contenders By Quality Scores",
      "id": 135148116,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1a715141ace3b115707a223df8914be7859358185883c42415537be64b013a81"
    }
  },
  {
    "ts": null,
    "headline": "American Century Focused Global Growth Fund Q1 2025 Commentary",
    "summary": "American Century Focused Global Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=b91c24de266e7b58acc384ba801ca93a4ad2c043e97768df28382dc54a6b85c9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749546000,
      "headline": "American Century Focused Global Growth Fund Q1 2025 Commentary",
      "id": 135148102,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b91c24de266e7b58acc384ba801ca93a4ad2c043e97768df28382dc54a6b85c9"
    }
  },
  {
    "ts": null,
    "headline": "2 Weight Loss Drug Stocks That Are Screaming Buys in June",
    "summary": "These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.",
    "url": "https://finnhub.io/api/news?id=0df806b4fe63cafc62ebe86f264ebb276ae73c43ca88b1a130edf449c9657579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749540780,
      "headline": "2 Weight Loss Drug Stocks That Are Screaming Buys in June",
      "id": 135148184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.",
      "url": "https://finnhub.io/api/news?id=0df806b4fe63cafc62ebe86f264ebb276ae73c43ca88b1a130edf449c9657579"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs",
    "summary": "$870 million agreement blends injectable and oral obesity treatment",
    "url": "https://finnhub.io/api/news?id=b44746ed9b2974544437389a588c1636190a6c0d06a7669dbfdd429a50b42fc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749517146,
      "headline": "Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs",
      "id": 135140846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "$870 million agreement blends injectable and oral obesity treatment",
      "url": "https://finnhub.io/api/news?id=b44746ed9b2974544437389a588c1636190a6c0d06a7669dbfdd429a50b42fc6"
    }
  }
]